Growth after Hematopoietic Stem Cell Transplantation in Children with Acute Myeloid Leukemia.
10.3346/jkms.2013.28.1.106
- Author:
Seung Joon CHUNG
1
;
Seung Wan PARK
;
Min Kyoung KIM
;
Min Jae KANG
;
Young Ah LEE
;
Seong Yong LEE
;
Choong Ho SHIN
;
Sei Won YANG
;
Hyoung Jin KANG
;
Kyung Duk PARK
;
Hee Young SHIN
;
Hyo Seop AHN
Author Information
1. Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics, Seoul National University Hospital, Seoul, Korea. chshinpd@snu.ac.kr
- Publication Type:Original Article
- Keywords:
Hematopoietic Stem Cell Transplantation;
Growth;
Radiotherapy;
Total Body Irradiation;
Acute Myeloid Leukemia
- MeSH:
Adolescent;
Body Height/*radiation effects;
Child;
Child, Preschool;
Female;
Graft vs Host Disease/pathology/prevention & control;
*Hematopoietic Stem Cell Transplantation;
Humans;
Hypogonadism/drug therapy/pathology;
Infant;
Leukemia, Myeloid, Acute/radiotherapy/*therapy;
Male;
Recurrence;
Retrospective Studies;
Risk Factors;
Steroids/therapeutic use
- From:Journal of Korean Medical Science
2013;28(1):106-113
- CountryRepublic of Korea
- Language:English
-
Abstract:
Previous studies have shown that hematopoietic stem cell transplantation (HSCT) may result in growth impairment. The purpose of this study was to evaluate the growth during 5 yr after HSCT and to determine factors that influence final adult height (FAH). We retrospectively reviewed the medical records of acute myeloid leukemia (AML) patients who received HSCT. Among a total of 37 eligible patients, we selected 24 patients who began puberty at 5 yr after HSCT (Group 1) and 19 patients who reached FAH without relapse (Group 2). In Group 1, with younger age at HSCT, sex, steroid treatment, hypogonadism and hypothyroidism were not significantly associated with growth impairment 5 yr after HSCT. History of radiotherapy (RT) significantly impaired the 5 yr growth after HSCT. Chronic graft-versus-host disease (cGVHD) only temporarily impaired growth after HSCT. In Group 2, with younger age at HSCT, steroid treatment and hypogonadism did not significantly reduce FAH. History of RT significantly reduced FAH. Growth impairment after HSCT may occur in AML patients, but in patients without a history of RT, growth impairment seemed to be temporary and was mitigated by catch-up growth.
